Back to News
Dec 15, 2025 4:00 PM

Johnson & Johnson Gets Target Hike, But BofA Flags Modest Pipeline Impact

The U.S. Food and Drug Administration on Monday awarded a national priority voucher to Johnson & Johnson’s (NYSE:JNJ) Tecvayli (teclistamab) in combination with daratumumab for relapsed/refractory multiple myeloma.

This brings the total number of products awarded under the Commissioner's National Priority Voucher pilot program to 16.

Johnson & Johnson sells daratumumab under the brand names Darzalex, Darzalex Faspro.

In the Phase 3 trial data released in November, Tec-Dara showed significant improvements over the standard of care in both progression-free survival and overall survival among patients previously treated with one ...